Pfizer lifts 2026 sales outlook to $62B-$64B

Pfizer (PFE) beat third-quarter estimates on Tuesday November 3 and raised its 2026 sales forecast to $62 billion to $64 billion, citing strong results so far this year. Its blood thinner Eliquis and newer drugs like the cancer treatment Padcev sold well, which made up for falling Covid sales. Cecile Guegan, a longtime company finance executive, became CFO. Tommy Tuberville holds PFE long.

Sources

Pfizer Beats Q3 Estimates and Raises 2026 Outlook to $62B-$64B in Sales, $2.95-$3.05 a Share, Names Cecile Guegan CFO
The whole story · updated
CN
CNBC
·
Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in